Bioavailability of ifosfamide in patients with bronchial carcinoma.
AffiliationDepartment of Medical Oncology, Christie Hospital and Holt Radium Institute, M20 9BX Manchester, UK.
MetadataShow full item record
AbstractThe pharmacokinetics of ifosfamide (I) were determined in ten patients with bronchogenic carcinoma. In seven patients, doses of 1 and 2 g (I) were given both as a bolus orally and later intravenously and were well tolerated. A further three patients received 5 g (I) as a single oral dose but in two this produced reversible CNS toxicity and severe vomiting. The area under the curve (AUC, microgram . h . l-1) for the 1-g dose was the same following oral and i.v. treatment and this was also true for the 2-g doses. There was a proportionate increase in the AUC for the 5-g oral dose, indicating 100% bioavailability at all three dose levels. We conclude that doses up to 2 g by mouth represent a well-tolerated alternative route of administration.
CitationBioavailability of ifosfamide in patients with bronchial carcinoma. 1986, 18 (3):261-4 Cancer Chemother. Pharmacol.
JournalCancer Chemotherapy and Pharmacology